

## Program

### Comprehensive Cancer Center Zurich

#### 7th Zurich Immuno-Oncology Symposium

Wednesday, March 1st, 2023, 9.00 a.m. – 5.00 p.m.

Hybrid Event



Organization: Comprehensive Cancer Center Zurich, Rämistrasse 100,  
8091 Zurich, Switzerland, [www.ccz.usz.ch](http://www.ccz.usz.ch), [cccz@usz.ch](mailto:cccz@usz.ch)

Credits: SGMO tbd

9.00 a.m.

#### Welcome

Markus G. Manz, University Hospital Zurich

#### Session 1: Patrick Roth

9.05 a.m.

#### Improving TIL-therapy in cancer

George Coukos, CHUV Lausanne

9.35 a.m.

#### PD1 resistant Melanoma: The latest drug developments

Reinhard Dummer, University Hospital Zurich

10.05 a.m.

#### Immunocytokines in non-melanoma skin cancer

Antonio Cozzio, Hospital St. Gallen

10.35 a.m.

#### Coffee Break

10.50 a.m.

#### Synergy of checkpoint inhibition and immuno-stimulation

Mélanie Tichet, Hanahan Lab Lausanne

11.20 a.m.

#### T-cell engaging Antibodies in hematologic malignancies

Marion Subklewe, University Hospital Munich

11.40 a.m.

#### Lunch Break

#### Session 2: Markus G. Manz

12.30 p.m.

#### Short Talk: Darpin-based, multiple antigen-directed T-cell engagers and activators

Nicolas Leupin, Chief Medical Officer Molecular Partners Zurich

12.50 p.m.

#### Short Talk: Combined T-cell engaging and checkpoint inhibiting antibodies in plasma cell neoplasia (LocATE)


Leonardo Borrás, Chief Scientific Officer, CDR-Life, Zurich

Kindly supported by:

## Program

- 1.10 p.m.**      **Harnessing macrophage checkpoints to treat cancer**  
Alexandre Theocharides, University Hospital Zurich
- 1.40 p.m.**      **Microglia activation against glioblastoma**  
Gregor Hutter, University of Basel
- 2.10 p.m.**      **Short Talk: DNA-encoded libraries for discovery of new surface targets**  
Dario Neri, CSO Pilochem Zurich
- 2.30 p.m.**      **Coffee Break**
- Session 3: Felix Beuschlein**
- 2.45 p.m.**      **Short Talk: Academic virus-free CAR T-cell development**  
Chiara Magnani, University Hospital Zürich
- 3.05 p.m.**      **Universal CAR T-cells: proof of concept studies**  
Michael Bachmann, HZDR Dresden
- 3.35 p.m.**      **CAR T-cells in combination with RNA-vaccination in advanced solid tumors**  
Andreas Mackensen, University Hospital Erlangen
- 4.05 p.m.**      **New targets for CAR-T cells in hematology and oncology**  
Michael Hudecek, University Hospital Würzburg
- 4.35 p.m.**      **Short Talk: Targeted RNA-CAR mediated immunotherapy against glioblastoma**  
Tobias Weiss, University Hospital Zurich
- 4.55 p.m.**      **Wrap-up**

Kindly supported by:



## Comprehensive Cancer Center Zurich

### 7th Zurich Immuno-Oncology Symposium

Wednesday, March 1st, 2023, 9.00 a.m. – 5.00 p.m.

Hybrid Event

